2% to $21. B2Gold Declares Fourth Quarter 2023 Dividend. Theratechnologies’ R&D staff is bearing the brunt of. Theratechnologies, Inc. For investor inquiries: Leah Gibson. (TH. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. S. 46. com. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. With the company starting 2023 with 8,725 employees, that’s an 11. com uses cookies on this site. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. The firm offers its product under the brand name of. com 10/16/2023. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. acts as investment manager. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Theratechnologies has generated ($1. US Headquarters. T. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. By continuing to use our service, you agree to our use of cookies. . TH Stock Message Board for Investors. The price has fallen in 7 of the last 10 days and is down by -30. We also use them to share usage information with our partners. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. Forecast to breakeven in 2024 Jul 15. By continuing to use our service, you agree to our use of cookies. MONTREAL, Aug. MONTREAL, Sept. stock news by MarketWatch. MONTREAL, Dec. 1-438. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). - Cash, bonds and money market funds of US$22. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Agreement in principle on key amendments to loan. 81 million for the quarter. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Thank you. Denis Boucher. com uses cookies on this site. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. MONTREAL, Oct. Theratechnologies Stock Price, News and Company Updates. Website. Biopharmaceutical company Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. Browse posts by Sector and Subsector. European Headquarters. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. La Bourse de Toronto a perdu. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 25 to $1. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. This news release constitutes a. Herein, we report. Theratechnologies Inc. We also use them to share usage. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. Theratechnologies Inc. (THTX) stock. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Follow. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. 72%. 1-514-336-7800. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 617-356-1009. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 Consolidated Revenue Growth of 17% to $20. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. com. com. 65 per cent to C$1. Stockhouse. Apr 14, 2020, 8:30 a. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. TO) on CEO. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. FY2023 revenue guidance range set between $90 million and $95 million. Losses were -47. com uses cookies on this site. This module allows you to check different measures of market premium (i. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Theratechnologies Appoints New Board Member. We also use them to share usage. 71. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. L. Christian Marsolais, Ph. Market Cap. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Investor Relations. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. com uses cookies on this site. TH | Complete Theratechnologies Inc. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. MONTREAL, Feb. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 08 (+6. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. 31K. Company Participants. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is the Company’s proprietary peptide linked to. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 00, suggesting a possible upside of. THERATECHNOLOGIES INC. . T. stockhouse. VANCOUVER, British Columbia, Nov. Theratechnologies inc. stock news by MarketWatch. - Q3 2022 North American Revenue Growth of 19%. Cookies are used to offer you a better browsing experience and to analyze our traffic. 4 million. com uses cookies on this site. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 67, which is an increase of 1,144. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. A high-level overview of Theratechnologies Inc. FY2023 revenue guidance range set between $90 million and $95 million. It is the Company’s proprietary. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. FAQ – Utilisateurs de TMX Argent NOUVEAU. - October 10, 2023) - KO Gold Inc. Once expert advice is considered, the Company. By continuing to use our service, you agree to our use of cookies. Focused on small-cap companies and sectors. THERATECHNOLOGIES INC. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. The price has fallen in 5 of the last 10 days. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. Story. Theratechnologies Inc. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Cookies are used to offer you a better browsing experience and to analyze our. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . is an employee of TaiMed Biologics USA, Inc. Stockhouse. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Consensus forecasts updated Jul 21. Stockhouse. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. com uses cookies on this site. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. The business had revenue of $27. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. For investor inquiries: Leah Gibson. Theratechnologies Inc. Their average twelve-month price target is $36. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. Theratechnologies to Announce Financial Results for Its First Quarter 2022. 51 to 200 Employees. com uses cookies on this site. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Cookies are used to offer you a better browsing experience and to. 03) EPS for the quarter, beating the consensus estimate of ($0. Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. These companies provide a lot of detail to the OTC Markets Group including audited financials. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. US Headquarters. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Theratechnologies Provides Details About R&D Day Webcast. Investor Relations. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. We also use them to share usage information with our partners. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. 06 million, an increase of 14. Vice President, Communications and Corporate Affairs. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Register for your free account today at data. 04) earnings per share (EPS) for the quarter. m. - TH1902 Phase 1 basket trial proceeding as planned. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. We also use them to share usage information with our partners. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. The Theratechnologies Inc. com uses cookies on this site. 4%. Theratechnologies Inc. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 11/05/2020 4:15:02 PM. Free cash flow. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. Their THTX share price targets range from $36. 5%. View recently published Stock News reports from independent reports and journalists. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Theratechnologies Inc. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. T. MONTREAL, Dec. M. TH | September 5, 2023. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. home message. 2. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Katana shareholders will. com uses cookies on this site. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. 8 million. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. T. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. European Headquarters. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. This news release constitutes a “designated news release” for the purposes of the Company’s. However, only about 4% of the stocks on the OTC market fall into this category. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. - 2023 Q3 positive adjusted EBITDA to be achieved. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00 in the next twelve months. GUD | Complete Knight Therapeutics Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. By Nick Paul Taylor Jul 12, 2023 8:57am. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. We also use them to share usage. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. H. There are 102 news items for this page. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. We also use them to share usage. Stockhouse. 's motion for leave to commence. com uses cookies on this site. TH | July 20, 2023. 9 million, adjusted EBITDA of $2. By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. 04) earnings per share (EPS) for the quarter. Stockhouse. About SORT1+ Technology™ and TH1902. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. com uses cookies on this site. . By continuing to use our service, you agree to our use of cookies. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. The company reported ($0. 8 and 1. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Conjugating the short peptide with various anti-cancer agents allows for. This news release constitutes a “designated news release” for the purposes. MONTREAL, Oct. By continuing to use our service, you agree to our use of cookies. Betteryear2. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Microsoft to invest $500M in Quebec AI economy. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. NCU. Montréal, Québec, Canada . 514-336-7800. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Further. L. By continuing to use our service, you agree to our use of cookies. 23) earnings per share over the last year ( ($1. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech.